New Post-Hoc Analysis of Pooled Phase 3 Data Shows That Inpefa (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction

Analysis adds to the body of evidence differentiating INPEFA as a dual oral inhibitor of SGLT2 and SGLT1

Related Keywords

Lisbon ,Lisboa ,Portugal ,United States ,American ,Craig Granowitz ,Lexicon Pharmaceuticals Inc ,American Heart Association ,American College Of Cardiology ,Nasdaq ,Annual Congress ,Heart Failure Association ,European Society ,American College ,